eCM (Eur Cell Mater / e Cells & Materials) Not-for-Profit Open Access
Created by Scientists, for Scientists
 ISSN:1473-2262         NLM:100973416 (link)         DOI:10.22203/eCM

2012   Volume No 24 – pages 107-117

Title: FGF18 augments osseointegration of intra-medullary implants in osteopenic FGFR3-/- mice

Author: A Carli, C Gao, M Khayyat-Kholghi, A Li, H Wang, C Ladel, EJ Harvey, JE Henderson

Address: Division of Orthopaedic Surgery, Department. of Surgery, C9.133 Montreal General Hospital, 1650 Cedar Ave, Montreal, Quebec, Canada H3G 1A4

E-mail: janet.henderson at mcgill.ca

Key Words: FGF18; FGFR3-/- mice; bone quality; bone regeneration; implant fixation.

Publication date: July 24th 2012

Abstract: Enhancement of endogenous bone regeneration is a priority for integration of joint replacement hardware with host bone for stable fixation of the prosthesis. Fibroblast Growth Factor (FGF) 18 regulates skeletal development and could therefore have applications for bone regeneration and skeletal repair. This study was designed to determine if treatment with FGF 18 would promote bone regeneration and integration of orthopedic hardware in FGF receptor 3 deficient (FGFR3-/-) mice, previously characterized with impaired bone formation. Rigid nylon rods coated with 200 nm of titanium were implanted bilaterally in the femora of adult FGFR3-/- and FGFR3+/+ mice to mimic human orthopedic hardware. At the time of surgery, LEFT femora received an intramedullary injection of 0.5 μg FGF18 (Merck Serono) and RIGHT femora received PBS as a control. Treatment with FGF18 resulted in a significant increase in peri-implant bone formation in both FGFR3+/+ and FGFR3-/- mice, with the peri-implant fibrous tissue frequently seen in FGFR3-/- mice being largely replaced by bone. The results of this pre-clinical study support the conjecture that FGF18 could be used in the clinical setting to promote integration of orthopedic hardware in poor quality bone.

Article download: Pages 107-117 (PDF file)
DOI: 10.22203/eCM.v024a08